Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
Tomas UherEva Kubala HavrdovaPascal BenkertNiels P BergslandJan KrasenskyBarbora SrpovaMichael DwyerMichaela TyblovaStephanie MeierManuela VaneckovaDana HorakovaRobert ZivadinovDavid LeppertTomas KalincikJens KuhlePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
sNfL improves the ability to identify patients at higher risk of future disease activity, beyond their NEDA-3 status. Measurement of sNfL may assist clinicians in decision-making by providing more sensitive prognostic information.